Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of TAK-831 in Healthy Subjects
NCT03706469Phase 1Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Oct 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of luvadaxistat in schizophrenia and Friedreich's ataxia (FA) (4 arms), sponsored by Neurocrine Biosciences. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration, Area Under the Plasma Concentration-time Curve From Time 0 to Infinity and 1 more. Started Oct 2018; status: completed.
02
Drugs
luvadaxistat
03
Conditions
schizophreniaFriedreich's ataxia (FA)
Beyond the preview
Go deeper on NCT03706469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03706469.